Prosensa Holding NV
(NASDAQ : RNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.03%183.551.1%$846.87m
GILDGilead Sciences, Inc.
-1.04%80.700.9%$816.69m
CELGCelgene Corporation
-0.92%95.261.2%$791.42m
JUNOJuno Therapeutics, Inc.
-0.41%85.1013.5%$584.15m
BIIBBiogen Inc.
-2.51%291.871.2%$500.99m
REGNRegeneron Pharmaceuticals, Inc.
-0.31%332.152.7%$399.78m
VRTXVertex Pharmaceuticals Incorporated
-0.14%160.721.9%$358.41m
ALXNAlexion Pharmaceuticals, Inc.
-1.83%120.472.0%$256.63m
NKTRNektar Therapeutics
1.57%83.436.0%$246.17m
ILMNIllumina, Inc.
0.03%229.203.5%$234.08m
BLUEBluebird Bio, Inc.
2.25%213.3516.1%$201.76m
AAgilent Technologies, Inc.
-0.11%71.941.5%$173.78m
INCYIncyte Corporation
0.51%86.032.5%$158.32m
EXASExact Sciences Corporation
-0.57%48.8626.0%$132.16m
BMRNBioMarin Pharmaceutical Inc.
-0.16%84.984.4%$122.34m

Company Profile

Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands.